Sofinnova Investments
| Type | Private |
|---|---|
| Industry | Venture capital |
| Founded | 1976 (U.S.) |
| Founders | Jean DelÃĐage (U.S. operations) Alain Azan |
| Headquarters | Menlo Park, California , United States |
| Key people | Jim Healy, Managing Partner Maha Katabi, General Partner Eric Delbridge, General Partner |
| AUM | US$4.4 billion (2025) |
| Website | www |
Sofinnova Investments is an American investment firm headquartered in Menlo Park, California, with offices in Boston and New York City. It invests in private and public equity across the life sciences industry.[1][2][3] As of 2025 it reported approximately US$4.4 billion in assets under management and committed capital.[2]
History
[edit]Sofinnova Investments traces its origins to France, where Sofinnova S.A. was founded in Paris in 1972. In 1976 the firm established a United States presence in San Francisco, California, led by Jean DelÃĐage.[4] DelÃĐage was an early investor in Genentech, reportedly writing a US$50,000 cheque to the company in 1977.[5]
In 1997, the global Sofinnova organization was restructured into two independent management companies: the United States firm, then known as Sofinnova Ventures, and the Paris-based Sofinnova Partners. The two firms have been independent since the split.[6]
From the mid-2000s the firm concentrated on biopharmaceutical investing: its seventh fund (2006) was primarily focused on therapeutics, and by its eighth fund (2011) it invested exclusively in the sector.[7][8][9]
In 2017, the firm launched an all-cap, value-oriented, long/short public-equity strategy in global therapeutics. The vehicle, Sofinnova BioEquities, expanded the firm's ability to invest across the public markets while remaining focused on the healthcare and biopharmaceutical sectors and is led by general partner Eric Delbridge.[10]
In 2019, the firm changed its name from Sofinnova Ventures to Sofinnova Investments; the change is recorded in its filings with the U.S. Securities and Exchange Commission between November 2018 and February 2019. The new name aligned the organization's brand with its broader platform spanning private and public healthcare investing.[2][11]
The firm's eleventh venture fund closed at US$500 million in 2023.[12][13] A twelfth fund, targeting US$550 million, began raising in 2024.[14]
References
[edit]- â Timmerman, Luke (20 November 2017). "12 VCs who matter in biotech, but you hardly ever read about". Timmerman Report. Retrieved 2026-07-18.
- 1 2 3 "Form ADV: Sofinnova Investments, Inc". Investment Adviser Public Disclosure. U.S. Securities and Exchange Commission. Retrieved 2026-07-18.
- â "Three Health-Care Firms Take Space at 27 West 24th Street". Commercial Observer. September 2022. Retrieved 2026-07-18.
- â Primack, Dan (18 March 2011). "VC pioneer Jean Deleage passes away". Fortune. Retrieved 2026-07-18.
- â Bernstein, Karen (11 April 2011). "A Remembrance: The venture capitalist as artist". BioCentury. Retrieved 2026-07-18.
- â "About". Sofinnova Investments. Retrieved 2026-07-18.
- â "Form D/A: Sofinnova Venture Partners VIII, L.P." EDGAR. U.S. Securities and Exchange Commission. 17 October 2011. Retrieved 2026-07-18.
- â "Sofinnova Raises $500 Million Biotech Venture Fund" (Press release). PR Newswire. 23 July 2014. Retrieved 2026-07-18.
- â "Sofinnova Raises $650 Million Biotech-Focused Venture Fund" (Press release). PR Newswire. 17 October 2016. Retrieved 2026-07-18.
- â "Form D: Sofinnova BioEquities, LP". FormDs.com. U.S. Securities and Exchange Commission (Form D data). 2017. Retrieved 2026-07-18.
- â "Sofinnova Investments (homepage)". Internet Archive (Wayback Machine). 1 February 2019. Retrieved 2026-07-18.
- â "Form D/A: Sofinnova Venture Partners XI, L.P." EDGAR. U.S. Securities and Exchange Commission. 11 September 2023. Retrieved 2026-07-18.
- â Hibbison, Ryan (15 September 2023). "Sofinnova Investments ends run of increasingly larger funds". Venture Capital Journal. Retrieved 2026-07-18.
- â "Form D: Sofinnova Venture Partners XII, L.P." EDGAR. U.S. Securities and Exchange Commission. 19 December 2024. Retrieved 2026-07-18.
